June 27, 2022
TAIZHOU, China, June 27, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. is pleased to announce that, the Group has recently received the clinical trial approval (the"Clinical Trial Approval") for its R520A, a mRNA COVID-19 vaccine ("R520A"), from the Food and Drug Administration...
Source URL: https://www.prnewswire.com:443/news-releases/clinical-trial-approval-for-mrna-covid-19-vaccine-for-omicron-variant-in-the-philippines-301575485.html
|
